Gold is emerging as a potential therapeutic agent in the treatment of arthritis, cancer and AIDS. The therapeutic mechanism of arthritic gold drugs and their modification in the presence of stomach hydrochloric acid, in the joints, and in the presence of mild and strong oxidizing agents is a matter of debate. It is believed that gold affects the entire immune response and reduces its potency and limits its oxidizing nature. DNA apparently is not the main target of gold in cancer treatment. Rheumatoid arthritis, cancer, heart diseases and recently AIDS have all been targeted with gold nanoparticles therapy. The era of gold nanoparticles started with cancer imaging and treatment studies. Gold nanoparticles have emerged as smart drug vehicles.
Introduction
While ancient civilizations may not have known exactly what made gold so valuable, there is no challenge to its exponential influence in our life. The medicinal characters of gold have been realized since the ancient history of Egypt. Gold in the form of liquid was used by the Egyptians to restore youth and ward off diseases and evil spirits [1] [2] [3] . In the eighth century CE, Jabir ibn Hayyan produced the gold acid by dissolving gold in aqua regia [4] . Robert Boyle noted that gold could be precipitated into a crystalline salt after dissolving in aqua regia [5] . Gold was dissolved in aqua regia, diluted with water, and then precipitated with potassium hydroxide solution [4] . Colloidal gold solution in modern times [6] [7] [8] [9] [10] was prepared by the great alchemist Paracelsus and called his purple solution potable gold.
Gold syrup was used in the 17 th century for the treatment of ailments caused by a decrease in the vital spirits [11] . In the 19 th century, gold chloride mixture with sodium chloride was used as a drug for the treatment of syphilis [6] , which was later used in many of the European pharmacopoeias [7] . In 1857, Faraday prepared colloidal gold [8] . Modern medicine of gold began with the bacteriostatic role of K[Au(CN)2] towards the tubercle bacillus [12] which in the 1920s was used for tuberculosis therapy. Chrysotherapy is the modern term used for the role of gold in medicine. The early gold compounds (drugs) used were the water soluble, injectable gold(I) thiolates such as aurothiosulfate (sanocrysin), aurothiomalate (myocrysine) and aurothioglucose (solganol). In 1976, triethylphosphine gold(I) tetraacetylthioglucose (auranofin) was approved by the FDA as an orally active drug for the treatment of rheumatoid arthritis (RA) (Figure 1 ) [13, 14] .
Rheumatoid Arthritis
Rheumatoid arthritis is accompanied by erosion of the joints, disfigurements, immobility, and pain [15] . Highly toxic reactive oxygen species (ROS) such as superoxide (O2 − ) (Equations 1-6) [16] are produced by oxidative burst. Superoxide is converted to hydrogen peroxide (H2O2) when catalyzed by superoxide dismutase (SOD, a class of enzymes that catalyzes the dismutation of superoxide into hydrogen peroxide and oxygen). In the presence of transition metal ions such as Fe(II), hydrogen peroxide and superoxide are converted to highly reactive hydroxyl radicals (OH•). Additionally, the enzyme myeloperoxidase catalyzes the oxidation of chloride to hypochlorite (OCl 
Gold Oxidation States
Gold exists in a number of oxidation states: -I, 0, I, II, III, IV and V; however, only gold 0, I and III are known to be stable. Gold(I) is thermodynamically more stable than gold(III) [17] . Many gold(III) complexes are strong oxidizing agents and generally toxic in biological systems (Equations 7-9). Gold oxidation state III is accessible under physiologically oxidizing conditions. Thus, a redox cycle is initiated by the reduction of gold(III) to gold(I) by biological reductants [18] .
The chemistry of gold differs greatly from other elements in the same group such as copper and silver. Some differences can be ascribed to the relativistic effects that perturb the 6s orbital in gold, but are not significant for the outer valence orbitals of copper and silver [19] . Gold(I) is a soft metal ion and therefore has a preference for sulfur and carbon donor ligands [20] . [21] . Extended X-ray absorption fine structure (EXAFS) of solganol shows a 1:1 polymeric complex with bridging thiolate sulfur centers and gold-gold contacts of less than 3.6 Å [22] . Myochrysine analogue [CsNa2HAu2(Tm)2]n was crystallized using hanging drop vapor diffusion technique (Figure 2 ). X-ray crystal structure of a side view of the two intertwined helices shows that the gold-sulfur chain is linear at gold and bent at sulfur. The polymeric structure shows the closest inter-strand gold-gold distance of 3.227(5) Å [23] . In sanocrysin drug, Na3[Au(S2O3)2] 2H2O, the gold center is bonded to the sulfur atoms from the two thiosulfate moieties in a nearly linear arrangement. The anions are relatively close, giving a short gold-gold distance of 3.302 Å [24] . Auranofin X-ray structure shows a nearly linear arrangement of phosphine-gold-sulfur, P-Au-S angle of 173.6° [25] . The glucopyranose ring exists in chair conformation with all groups oriented equatorially. The β-configuration of the anomeric C-S bond on the basis of synthesis and optical rotation was confirmed.
Structure of Arthritic Gold Drugs

Mechanism of Action and Fate of Gold Drugs
Fate of Auranofin in Stomach Hydrochloric Acid
The effect of aqueous HCl on auranofin was studied at stomach pH 1.0. The cationic dinuclear gold(I) complex [RS(Et3PAu)2] + (RS = 2,3,4,6-tetra-acetyl-1-thio-beta-D-glucopyranosato) was proposed as one of the products (Equation 10). The mechanism of auranofin reaction with HCl occurs by the formation of a three-coordinate gold complex through an associative step which involves the coordination of chloride [26] .
Interaction of Gold Drugs with Proteins "Shuttle Thiol Mechanism"
The major binding site for gold drugs in plasma is the cysteine-34 free thiol of human serum albumin [27] . The thiolate of the gold drug being exchanged with the cysteine-34 of albumin induces a structural transition from "buried" to "exposed" (Figure 3 ). This is consistent with the rapid elimination of the thiolate than gold(I) from the bloodstream. Gold(I) is likely to undergo a thiol exchange reaction and penetrate the cell by the shuttle thiol mechanism [28] . The first order reaction rate of albumin and zero with respect to auranofin indicates that auranofin stays intact for a few seconds before it exchanges in the blood.
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Mild Oxidation of Auranofin
A crucial aspect in the oxidation potential of arthritic drugs is the redox power of the cell environment and the in vivo conditions required to initiate the electron-transfer cycle. Administered arthritic gold thiolate drugs presumably dissociate in the body under oxidative conditions and undergo different metabolic processes.
Electrochemical oxidation of auranofin and its model complexes in dichloromethane studied by the Bruces shows two broad irreversible oxidation peaks [29] . It is likely that gold(I) is oxidized to gold(III) followed by a chemical step. Chemical oxidation of auranofin by the mild oxidizing agent ferrocenium cation, [Fc] + suggests that the oxidation in vivo may occur at potentials that are biologically accessible under normal cellular conditions [30, 31] . 
Reduction of Gold(I) to Gold(0) in Joints "Aurosomes"
The electrochemical reduction of auranofin in ethanol/water solvent mixture occurs at −0.50 V vs. SCE (−0.26 V vs. NHE) above pH 9.0. The number of electrons calculated in auranofin reduction is one, which corresponds to gold(I) to elemental gold reduction [34] .
Gold(0) is formed in vivo from gold(I) thiolate drugs according to electron microscopy studies [35] . Electron-dense deposits of gold(0) were located in the macrophage-like cells of the synovial tissues in patients infected with rheumatoid arthritis. These deposits are contained within lysosomes ('aurosomes') ( Figure 5 ) [35, 36] . To test the hypothesis that gold(0) might be pharmacologically active, a colloidal gold was administered subcutaneously and it proved to be almost 1000 times more potent than myocrysine [37] . 
Strong Oxidation of Gold Drugs
Gold(I) drugs are susceptible to oxidation to gold(III) by the strong oxidizing agent myeloperoxidase (MPO) generated hypochlorite (OCl − ) (Scheme 1). Strong oxidizing agents activate the three redox active centers in gold drugs; sulfur to sulfonate, phosphine to phosphine oxide and gold(I) to gold(III) [38] [39] [40] . This results in the formation of three metabolites with various excretion rates. Gold(III) appears only after the initial oxidation of sulfur and phosphine. Gold(I) is likely to be oxidized to gold(III) which is affected by the concentration of MPO, H2O2, and gold(I).
Activation of Gold(I) Drugs by Forming Gold(I) Cyanide Metabolite
The stability constant for gold (I) 
Smoking and the Clinical Response to Gold Drugs
Smokers treated with gold drugs are reported to have higher concentrations of gold in their red blood cells compared with nonsmokers [48, 49] − is anticipated in smokers.
Toxicity of Gold Rheumatoid Drugs
Rheumatoid arthritis drugs are administered to alleviate the symptoms and to slow the disease progression. Skin rash and discoloration, oral ulcers and other side effects have been reported in patients treated with gold drugs. The negative effects of gold drugs can persist even after halting gold treatment [50] [51] [52] .
General Comments on the Mechanism of Action
Redox perturbation plays a major role in many diseases. Gold drugs utilize redox cycling in their action in the body. Understanding the activation step, i.e., disulfide activation, will ultimately support broader medicinal applications of the various types of therapeutic agents. Apart from the general belief that metal-based drugs function in the body by the e-shuttle mechanism, the "activation by redox" has become a more conceivable route in the therapeutic action.
Fackler demonstrated that mononuclear and dinuclear gold(I) complexes are capable of activating disulfides. The reaction of the disulfide PhCH2SSCH2Ph with [Au(PPh3)]NO3 formed a cationic gold cluster [Au2(R3P)2(μ-SR)]
+ [53] . The role that gold cation [Me3PAu] + plays in promoting disulfide bond cleavage was assessed by using tandem mass spectrometry. The [Me3PAu] + cation promoted disulfide bond cleavage of cystine. The most abundant S-S and C-S bond cleavage reactions were observed [54] . Theoretical studies on disulfide models suggest electrophilic and oxidative-addition mechanisms which are initiated by coordination of the gold species to the disulfide bond [55] . Fluorinated disulfides activate gold thiolate complexes by oxidative addition/reductive elimination processes under thermal and photochemical pathways ( Figure 6 ) [56] . Gold(III) intermediate is likely to form in gold thiolate drugs via similar processes.
Promising Gold Therapeutic Anticancer Properties
The interest in gold(III) as anticancer agent is a result of the current significance of the anticancer cisplatin, cis-diamminedichloroplatinum(II), [PtCl2(NH3)2] [57] . Although cisplatin has been used for a long time for the treatment of different types of cancer there are several limitations and drawbacks. Gold(III) compounds provided alternative class of drugs. Gold(III) compounds, isoelectronic (d 8 ) with platinum(II), form four-coordinate with a square planar geometry. Cisplatin complexes target DNA in their mechanism of action in cancer treatment, however gold cytotoxicity may originate from their ability to modify mitochondrial function [58, 59] .
The lipophilic phosphine gold compounds can readily enter the cells while the more hydrophilic oligomeric thiolates do not accumulate in cells, and are inactive in cancer treatment [60, 61] . Disphosphine gold(I) compound [(AuCl)2(dppe)], dppe = bis(diphenyl)phosphine, has shown activity against the M5076 reticulum cell sarcoma, subcutaneous mammary adenocarcinoma, and P388 leukemia [62] . In the presence of more dppe ligands, [(AuCl)2(dppe)] undergoes ring closure to form the tetrahedral compound cation [Au(dppe)2] + , which is suggested to be the active species (Equation 13 ). An important advantage of gold diphosphine compounds in cancer therapy is the ability to change the substituents on the phosphorous centers, and hence modify the lipophilicity or hydrophilicity [63] . Gold(I) phosphine compounds have shown antitumor activity, especially among cisplatin-resistant cell lines, but their clinical trials were halted due to acute toxicity in heart, liver, and lungs [58, 59, 64] .
Au
N CH 3 CH 3 X X , are similar to phosphine ligands in terms of their metal coordination chemistry [70] and have shown antimitochondrial activity [71] . An advantage of the NHC class is the ability to modify their hydrophilic and lipophilic properties by varying the substituents [72] . The rising use of gold complexes in cancer treatment has provided several complexes for trials but there is no mechanism of action yet on how gold enters the cell and the fate of the ligands associated with gold. Unlike arthritic drugs, gold cancer drugs have not been approved for marketing. The research in this area ascertained the fact that gold drugs are incorporated in the body and in a different pathway than platinum drugs.
Anti-HIV Activity of Gold
Water soluble gold-thiolate drugs solganol and myocrysine have shown promising results as anti HIV by ligand exchange mechanism of the reactive species bis(thiolato) gold(I) and acidic thiol groups exposed on viral surface proteins as well as by inhibition of reverse transcriptase in cell-free assays [73, 74] . Auranofin has shown an increase in the CD4+ count [75] . Gold cyanide was also reported to have anti-HIV activity through inhibition of reverse transcriptase [76] . Aurocyanide probably hinders HIV proliferation [77] . Gold(I) phosphine complexes were tested for potential inhibition of HIV enzymes supported by the fact that the presence of this group can result in lipophilicity [78] .
Current Status of Gold Nanoparticles Therapy
Gold nanoparticles area of research has been the hope for medicine in biomedical engineering [79] . Rheumatoid arthritis, cancer, heart diseases and recently AIDS have all been targeted with gold nanoparticles therapy. The era of gold nanoparticles started with cancer imaging and treatment. In heart diseases, gold nanoparticles have been utilized in the controlled release of nitric oxide from cardiovascular drugs. Gold nanoparticles have shown major contribution in "NO-enhanced medicines." It has been shown that gold nanoparticles can enrich and identify protein S-nitrosylation sites and catalyze nitric oxide generation from blood serum [80] . The process is ascribed to the self-assembly of a thiolate monolayer on the gold nanoparticles surface accompanied by the release of nitric oxide.
Gold nanoparticles have become of immense interest because of their extensive biomedical applications [81, 82] . However, biomedical use of gold nanoparticles must be further examined in terms of biocompatibility. Some questions have to be addressed such as: how toxic are gold nanoparticles and at what concentrations can they be injected in the body?
Conclusions
Investigating gold in the treatment of various diseases supported the developing field of metal-based drugs. The continuous efforts in chrysotherapy greatly included periods of great passion and complete dismissal. The current strong interest in gold research in arthritis, cancer and AIDS anchors the role of gold compounds in medicine. Gold is truly the standout of the metals and the new Gilded Hope for Medicine.
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